Kezar Life Sciences IncNASDAQ:KZR
- LAST PRICE7.6200
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots7.2100/ 50
- Ask / Lots7.5500/ 5
- Open / Previous Close--- / 7.6200
- Day Range---
- 52 Week Range
- Volume803
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | KZR |
|---|---|---|
| 09:32 ET | 100 | 7.5 |
| 09:33 ET | 100 | 7.499 |
| 09:37 ET | 4089 | 7.59 |
| 09:42 ET | 1200 | 7.62 |
| 09:50 ET | 262 | 7.565 |
| 09:57 ET | 262 | 7.5528 |
| 10:54 ET | 100 | 7.5 |
| 11:12 ET | 100 | 7.5 |
| 11:16 ET | 160 | 7.5 |
| 11:30 ET | 100 | 7.47 |
| 11:45 ET | 100 | 7.48 |
| 12:15 ET | 918 | 7.51 |
| 12:17 ET | 200 | 7.51 |
| 12:19 ET | 600 | 7.51 |
| 12:21 ET | 800 | 7.51 |
| 12:26 ET | 200 | 7.55 |
| 12:28 ET | 200 | 7.51 |
| 12:30 ET | 220 | 7.55 |
| 12:33 ET | 100 | 7.51 |
| 12:37 ET | 100 | 7.515 |
| 12:39 ET | 300 | 7.51 |
| 12:42 ET | 424 | 7.515 |
| 12:48 ET | 100 | 7.515 |
| 12:55 ET | 100 | 7.52 |
| 12:57 ET | 100 | 7.52 |
| 01:04 ET | 2559 | 7.52 |
| 01:08 ET | 498 | 7.52 |
| 01:09 ET | 200 | 7.525 |
| 01:13 ET | 338 | 7.53 |
| 01:18 ET | 300 | 7.505 |
| 01:33 ET | 500 | 7.535 |
| 01:45 ET | 100 | 7.54 |
| 01:51 ET | 606 | 7.54 |
| 01:54 ET | 100 | 7.54 |
| 02:02 ET | 100 | 7.54 |
| 02:03 ET | 398 | 7.55 |
| 02:14 ET | 800 | 7.55 |
| 02:20 ET | 700 | 7.535 |
| 02:21 ET | 200 | 7.535 |
| 02:25 ET | 100 | 7.535 |
| 02:27 ET | 400 | 7.53 |
| 02:30 ET | 100 | 7.53 |
| 02:34 ET | 100 | 7.53 |
| 02:36 ET | 200 | 7.53 |
| 02:39 ET | 200 | 7.535 |
| 02:45 ET | 300 | 7.53 |
| 02:48 ET | 652 | 7.555 |
| 02:50 ET | 261 | 7.555 |
| 02:52 ET | 410 | 7.555 |
| 02:54 ET | 403 | 7.555 |
| 02:56 ET | 237 | 7.555 |
| 02:57 ET | 320 | 7.555 |
| 02:59 ET | 401 | 7.55 |
| 03:01 ET | 833 | 7.555 |
| 03:03 ET | 300 | 7.555 |
| 03:06 ET | 307 | 7.555 |
| 03:08 ET | 200 | 7.555 |
| 03:10 ET | 371 | 7.55 |
| 03:12 ET | 500 | 7.55 |
| 03:14 ET | 400 | 7.55 |
| 03:15 ET | 400 | 7.555 |
| 03:17 ET | 100 | 7.555 |
| 03:19 ET | 548 | 7.555 |
| 03:21 ET | 400 | 7.54 |
| 03:24 ET | 493 | 7.57 |
| 03:26 ET | 100 | 7.57 |
| 03:28 ET | 651 | 7.57 |
| 03:30 ET | 264 | 7.57 |
| 03:32 ET | 574 | 7.57 |
| 03:33 ET | 288 | 7.55 |
| 03:35 ET | 600 | 7.57 |
| 03:37 ET | 300 | 7.575 |
| 03:39 ET | 500 | 7.58 |
| 03:42 ET | 600 | 7.5739 |
| 03:44 ET | 600 | 7.58 |
| 03:46 ET | 400 | 7.58 |
| 03:48 ET | 799 | 7.58 |
| 03:50 ET | 508 | 7.58 |
| 03:51 ET | 892 | 7.59 |
| 03:53 ET | 656 | 7.59 |
| 03:55 ET | 1100 | 7.59 |
| 03:57 ET | 400 | 7.65 |
| 04:00 ET | 13730 | 7.62 |
Nov 12, 2024
Kezar Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update, from 4:01PM ET on Tuesday Nov 12, 2024 by Dow Jones
4:01PM ET on Tuesday Nov 12, 2024 by Dow Jones*DJ Kezar Life Sciences 3Q Loss/Shr $2.78 >KZR, from 4:01PM ET on Tuesday Nov 12, 2024 by Dow Jones
4:01PM ET on Tuesday Nov 12, 2024 by Dow Jones
Nov 5, 2024
Glancy Prongay & Murray LLP Announces Investigation of Kezar Life Sciences, Inc. (KZR), from 10:58AM ET on Tuesday Nov 05, 2024 by Dow Jones
10:58AM ET on Tuesday Nov 05, 2024 by Dow Jones
Oct 28, 2024
*DJ Kezar Life Sciences Announces 1-for-10 Reverse Stock Split >KZR, from 8:30AM ET on Monday Oct 28, 2024 by Dow Jones
8:30AM ET on Monday Oct 28, 2024 by Dow JonesKezar Life Sciences Announces 1-for-10 Reverse Stock Split, from 8:30AM ET on Monday Oct 28, 2024 by Dow Jones
8:30AM ET on Monday Oct 28, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Kezar Life Sciences Inc | 556.0M | -0.6x | --- |
Mereo BioPharma Group PLC | 566.2M | 0.0x | --- |
Savara Inc | 556.0M | -7.3x | --- |
Corvus Pharmaceuticals Inc | 559.2M | -9.7x | --- |
MBX Biosciences Inc | 551.7M | 0.0x | --- |
Humacyte Inc | 547.6M | -3.3x | --- |
Company Information
Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer. The Company's lead product candidate, zetomipzomib, is a first-in-class selective immunoproteasome inhibitor that has completed Phase Ia testing in healthy volunteers and a Phase Ib/IIa clinical trial in patients with systemic lupus erythematosus (SLE), with or without lupus nephritis (LN). Its oncology product candidate, KZR-261, is a small molecule agent, targeting the Sec61 translocon and protein secretion pathway, being studied in an open-label Phase I clinical trial designed to evaluate safety and tolerability, pharmacokinetics and pharmacodynamics, as well to explore preliminary anti-tumor activity. This study is being conducted in two parts: dose escalation in patients with locally advanced or metastatic solid malignancies, and dose expansion in patients with selected tumor types.
Contact Information
- Headquarters
- 4000 Shoreline Ct Ste 300SOUTH SAN FRANCISCO, CA, United States 94080-2005
- Phone
- 650-822-5600
- Fax
- 302-636-5454
Executives
- Independent Chairman of the Board
- Graham Cooper
- Chief Executive Officer, Director
- Christopher Kirk
- Chief Financial Officer, Secretary
- Marc Belsky
- Chief Business Officer
- Nick Mordwinkin
- Chief Legal Officer
- Mark Schiller
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $556.0M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 73.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.25 |
EPS | $-13.15 |
Book Value | $25.77 |
P/E Ratio | -0.6x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
